NZ595087A - Novel amino azaheterocyclic carboxamides - Google Patents
Novel amino azaheterocyclic carboxamidesInfo
- Publication number
- NZ595087A NZ595087A NZ595087A NZ59508710A NZ595087A NZ 595087 A NZ595087 A NZ 595087A NZ 595087 A NZ595087 A NZ 595087A NZ 59508710 A NZ59508710 A NZ 59508710A NZ 595087 A NZ595087 A NZ 595087A
- Authority
- NZ
- New Zealand
- Prior art keywords
- quinazoline
- benzylamino
- carboxylic acid
- acid amide
- novel amino
- Prior art date
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract 2
- 150000003857 carboxamides Chemical class 0.000 title 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- ODMRNHOIGXFNFQ-UHFFFAOYSA-N 4-[[3-(3-methoxypropylcarbamoylamino)phenyl]methylamino]quinazoline-8-carboxamide Chemical compound COCCCNC(=O)NC1=CC=CC(CNC=2C3=CC=CC(=C3N=CN=2)C(N)=O)=C1 ODMRNHOIGXFNFQ-UHFFFAOYSA-N 0.000 abstract 1
- IXXXRLXHQHLRSJ-UHFFFAOYSA-N 4-[[3-[(4-bromobenzoyl)amino]phenyl]methylamino]quinazoline-8-carboxamide Chemical compound N1=CN=C2C(C(=O)N)=CC=CC2=C1NCC(C=1)=CC=CC=1NC(=O)C1=CC=C(Br)C=C1 IXXXRLXHQHLRSJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 carboxamide compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003335 secondary amines Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20735409P | 2009-02-11 | 2009-02-11 | |
| PCT/US2010/000313 WO2010093419A1 (en) | 2009-02-11 | 2010-02-04 | Novel amino azaheterocyclic carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595087A true NZ595087A (en) | 2013-03-28 |
Family
ID=42199208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595087A NZ595087A (en) | 2009-02-11 | 2010-02-04 | Novel amino azaheterocyclic carboxamides |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8637532B2 (enExample) |
| EP (1) | EP2396307B1 (enExample) |
| JP (1) | JP5642714B2 (enExample) |
| KR (1) | KR101699991B1 (enExample) |
| CN (1) | CN102317269B (enExample) |
| AR (1) | AR075396A1 (enExample) |
| AU (1) | AU2010214095B2 (enExample) |
| BR (1) | BRPI1008325A2 (enExample) |
| CA (1) | CA2751886C (enExample) |
| CL (1) | CL2011001967A1 (enExample) |
| DK (1) | DK2396307T3 (enExample) |
| EA (1) | EA020731B1 (enExample) |
| ES (1) | ES2527940T3 (enExample) |
| HR (1) | HRP20141239T1 (enExample) |
| IL (1) | IL214412A0 (enExample) |
| MX (1) | MX338354B (enExample) |
| MY (1) | MY160468A (enExample) |
| NZ (1) | NZ595087A (enExample) |
| PL (1) | PL2396307T3 (enExample) |
| PT (1) | PT2396307E (enExample) |
| SG (1) | SG173473A1 (enExample) |
| SI (1) | SI2396307T1 (enExample) |
| UA (1) | UA107188C2 (enExample) |
| WO (1) | WO2010093419A1 (enExample) |
| ZA (1) | ZA201106624B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| CN103140484B (zh) * | 2010-07-29 | 2015-04-22 | 默克专利有限公司 | 环状胺氮杂杂环甲酰胺 |
| PT2643313T (pt) * | 2010-11-24 | 2016-10-11 | Merck Patent Gmbh | Quinazolina carboxamida azetidinas |
| HRP20171655T1 (hr) | 2011-09-12 | 2017-12-15 | Merck Patent Gmbh | Derivati aminopirimidina za upotrebu kao modulatori aktivnosti kinaze |
| LT2755965T (lt) | 2011-09-12 | 2017-11-10 | Merck Patent Gmbh | Naujieji imidazolo aminai kaip kinazės aktyvumo moduliatoriai |
| PL2794571T3 (pl) * | 2011-12-22 | 2017-04-28 | Merck Patent Gmbh | Nowe heterocykliczne karboksyamidy jako modulatory aktywności kinazowej |
| US9315517B2 (en) | 2012-11-16 | 2016-04-19 | Merck Patent Gmbh | Imidazol-piperidinyl derivatives as modulators of kinase activity |
| WO2014078637A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| ES2821102T3 (es) * | 2012-11-29 | 2021-04-23 | Merck Patent Gmbh | Derivados de azaquinazolincarboxamida |
| RU2721418C2 (ru) | 2013-02-01 | 2020-05-19 | Веллстат Терапьютикс Корпорейшн | Соединения амина, имеющие противовоспалительную, противогрибковую, противопаразитарную и противораковую активность |
| SG10201900954SA (en) | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| RU2733401C2 (ru) | 2014-04-03 | 2020-10-01 | Мерк Патент Гмбх | Комбинации противораковых лекарств |
| CN104292170B (zh) * | 2014-09-22 | 2016-06-29 | 广西师范大学 | 具有抗肿瘤作用的喹唑啉-芳基脲衍生物及其应用 |
| CA2965336A1 (en) * | 2014-10-22 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| FR3066761B1 (fr) | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| WO2019006322A1 (en) * | 2017-06-30 | 2019-01-03 | The University Of North Carolina At Chapel Hill | HETEROCROMATINE GENE REPRESSION INHIBITORS |
| TWI827583B (zh) | 2018-03-08 | 2024-01-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物 |
| TWI853814B (zh) * | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CN109369634B (zh) * | 2018-12-19 | 2021-07-27 | 陕西国际商贸学院 | 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途 |
| RU2723481C1 (ru) * | 2019-10-03 | 2020-06-11 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УНИТАРНОЕ ПРЕДПРИЯТИЕ "ИНСТИТУТ ХИМИЧЕСКИХ РЕАКТИВОВ И ОСОБО ЧИСТЫХ ХИМИЧЕСКИХ ВЕЩЕСТВ НАЦИОНАЛЬНОГО ИССЛЕДОВАТЕЛЬСКОГО ЦЕНТРА "КУРЧАТОВСКИЙ ИНСТИТУТ" (НИЦ "Курчатовский институт - ИРЕА) | 4-[метил 4-(аминометил)циклогексанкарбоксилат]хиназолин и способ его получения |
| MA57518B1 (fr) | 2019-11-01 | 2025-12-31 | Syngenta Crop Protection Ag | Composés hétéroaromatiques bicycliques condensés à activité pesticide |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| CA3201799A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| JP2024527287A (ja) | 2021-06-24 | 2024-07-24 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤としての２－［３－［１［（キナゾリン－４－イル）アミノ］エチル］ピラジン－２－イル］チアゾール－５－カルボニトリル誘導体及び類似化合物 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| CA3245810A1 (en) * | 2022-04-11 | 2023-10-19 | Merck Patent Gmbh | PYRIDO[3,2-D]PYRIMIDINS USED AS HPK1 INHIBITORS |
| JP2025520650A (ja) | 2022-06-21 | 2025-07-03 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性な縮合二環式芳香族複素環式化合物 |
| CN115521474B (zh) * | 2022-09-30 | 2023-08-22 | 陕西科技大学 | 一种基于五重互穿氢键有机框架材料及其制备方法和应用 |
| WO2025228828A1 (en) * | 2024-04-29 | 2025-11-06 | Merck Patent Gmbh | Carboxamide compounds for the treatment and prevention of viral diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA805652B (en) * | 1979-09-14 | 1981-09-30 | New Zealand Dev Finance | Compounds having antitumour properties |
| GB8804445D0 (en) * | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| RU2002110461A (ru) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
| ATE503743T1 (de) * | 2000-04-27 | 2011-04-15 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| ES2305081T3 (es) * | 2000-06-28 | 2008-11-01 | Astrazeneca Ab | Derivados de quinozolina sustituidos y su uso como inhibidores. |
| CN100491372C (zh) * | 2001-12-24 | 2009-05-27 | 阿斯特拉曾尼卡有限公司 | 作为欧若拉激酶抑制剂的取代喹唑啉衍生物 |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CA2522595A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| CA2539339A1 (en) | 2003-09-30 | 2005-04-14 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CA2541989C (en) | 2003-10-24 | 2013-10-01 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| WO2005054237A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| JP2007513962A (ja) | 2003-12-09 | 2007-05-31 | アメリカ合衆国 | 免疫応答を抑制するため、または増殖性障害を治療するための方法 |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| US7776857B2 (en) * | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
-
2010
- 2010-02-04 DK DK10705453.8T patent/DK2396307T3/en active
- 2010-02-04 KR KR1020117021335A patent/KR101699991B1/ko active Active
- 2010-02-04 UA UAA201110411A patent/UA107188C2/ru unknown
- 2010-02-04 PL PL10705453T patent/PL2396307T3/pl unknown
- 2010-02-04 SI SI201030849T patent/SI2396307T1/sl unknown
- 2010-02-04 JP JP2011550122A patent/JP5642714B2/ja active Active
- 2010-02-04 HR HRP20141239AT patent/HRP20141239T1/hr unknown
- 2010-02-04 CN CN201080007165.1A patent/CN102317269B/zh active Active
- 2010-02-04 US US13/148,903 patent/US8637532B2/en active Active
- 2010-02-04 EA EA201101182A patent/EA020731B1/ru not_active IP Right Cessation
- 2010-02-04 MY MYPI2011003710A patent/MY160468A/en unknown
- 2010-02-04 AU AU2010214095A patent/AU2010214095B2/en active Active
- 2010-02-04 WO PCT/US2010/000313 patent/WO2010093419A1/en not_active Ceased
- 2010-02-04 MX MX2011008395A patent/MX338354B/es active IP Right Grant
- 2010-02-04 ES ES10705453.8T patent/ES2527940T3/es active Active
- 2010-02-04 PT PT107054538T patent/PT2396307E/pt unknown
- 2010-02-04 EP EP10705453.8A patent/EP2396307B1/en active Active
- 2010-02-04 CA CA2751886A patent/CA2751886C/en active Active
- 2010-02-04 NZ NZ595087A patent/NZ595087A/xx unknown
- 2010-02-04 SG SG2011055001A patent/SG173473A1/en unknown
- 2010-02-04 BR BRPI1008325-1A patent/BRPI1008325A2/pt not_active IP Right Cessation
- 2010-02-11 AR ARP100100376A patent/AR075396A1/es not_active Application Discontinuation
-
2011
- 2011-08-02 IL IL214412A patent/IL214412A0/en active IP Right Grant
- 2011-08-11 CL CL2011001967A patent/CL2011001967A1/es unknown
- 2011-09-09 ZA ZA2011/06624A patent/ZA201106624B/en unknown
-
2013
- 2013-12-13 US US14/105,974 patent/US9040560B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595087A (en) | Novel amino azaheterocyclic carboxamides | |
| EA201390265A1 (ru) | Амиды n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоновых кислот и их применение в качестве гербицидов | |
| IL269092A (en) | Process for preparing 2-(9h-carbazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide | |
| NZ604035A (en) | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | |
| EA201391320A1 (ru) | Амиды n-(1,3,4-оксадиазол-2-ил)арилкарбоновых кислот и их применение в качестве гербицидов | |
| NZ599008A (en) | 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors | |
| EA200601785A1 (ru) | Соединения и способы лечения дислипидемии | |
| PE20180177A1 (es) | Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
| BR112014010813A2 (pt) | n-(tetrazol-5-il)-aril-carboxamidas e n-(triazol-5-il)-aril-carboxamidas substituídas em 5-fenilo e sua utilização como herbicidas | |
| BRPI0813271A2 (pt) | Síntese regiosseletiva catalisada por cobre de benzimidazóis e azabenzimidazóis | |
| BRPI0519597A2 (pt) | derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose | |
| EA201100354A1 (ru) | Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)-метоксикарбониламинометил]бензамида (ms-275) | |
| PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20080319A1 (es) | Dihidrotienopirimidinas como agentes inhibidores de pde-4 | |
| UA110372C2 (en) | Amide n- (1,2,5-oxadiazoles-3-yl) -, n- (tetrazol-5-yl) - and n- (triazole-5-yl) bitsykloarylkarbonovoyi acid and their use as herbicides | |
| MX2010007588A (es) | Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor de esfingosina-1-fosfato (s1p). | |
| EA201792052A1 (ru) | Соли амидов n-(1,3,4-оксадиазол-2-ил)арил карбоновой кислоты и их применение в качестве гербицидов | |
| NZ612119A (en) | Use of sigma ligands in bone cancer pain | |
| NO20064200L (no) | Fremgangsmate for syntese av en CXCR4-antagonist | |
| HN2009001436A (es) | Nuevo procedimiento de sintesis de la agometatina | |
| BR112014005554A2 (pt) | aminas de imidazol como moduladores de atividade de quinase | |
| DE602005012811D1 (de) | Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd | |
| PE20120810A1 (es) | Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3 | |
| EA201100696A1 (ru) | 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 FEB 2017 BY CPA GLOBAL Effective date: 20131219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2018 BY CPA GLOBAL Effective date: 20161223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2019 BY CPA GLOBAL Effective date: 20171222 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2020 BY CPA GLOBAL Effective date: 20181220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2021 BY CPA GLOBAL Effective date: 20191219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2022 BY CPA GLOBAL Effective date: 20201224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2023 BY CPA GLOBAL Effective date: 20211223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2024 BY CPA GLOBAL Effective date: 20221224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2025 BY CPA GLOBAL Effective date: 20231221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241219 |